Literature DB >> 25143567

Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatment.

Javier R Guelfo1, Juan Macias1, Karin Neukam1, Federico A Di Lello2, Jose A Mira1, Nicolas Merchante1, María Mancebo1, Rocío Nuñez-Torres1, Juan A Pineda1, Luis M Real3.   

Abstract

The accuracy of LiPA 2.0 for hepatitis C virus 1 (HCV-1) subtype classification was analyzed. LiPA 2.0 genotype results from 101 HCV-1-infected patients were compared to genotype findings determined by direct core sequencing. Eleven (11%) samples were misclassified. Given the influence of the HCV-1-subtype in the anti-HCV therapy response, an alternative classification method is warranted.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25143567      PMCID： PMC4313243          DOI： 10.1128/JCM.02209-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  12 in total

Review 1.  Resistance to direct antiviral agents in patients with hepatitis C virus infection.

Authors:  Christoph Sarrazin; Stefan Zeuzem
Journal:  Gastroenterology       Date:  2009-12-16       Impact factor: 22.682

2.  MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods.

Authors:  Koichiro Tamura; Daniel Peterson; Nicholas Peterson; Glen Stecher; Masatoshi Nei; Sudhir Kumar
Journal:  Mol Biol Evol       Date:  2011-05-04       Impact factor: 16.240

3.  Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy.

Authors:  B Robertson; G Myers; C Howard; T Brettin; J Bukh; B Gaschen; T Gojobori; G Maertens; M Mizokami; O Nainan; S Netesov; K Nishioka; T Shin i; P Simmonds; D Smith; L Stuyver; A Weiner
Journal:  Arch Virol       Date:  1998       Impact factor: 2.574

4.  Comparison of three different HCV genotyping methods: core, NS5B sequence analysis and line probe assay.

Authors:  Qingxian Cai; Zhixin Zhao; Ying Liu; Xiaoqiong Shao; Zhiliang Gao
Journal:  Int J Mol Med       Date:  2012-12-12       Impact factor: 4.101

5.  Faldaprevir and deleobuvir for HCV genotype 1 infection.

Authors:  Stefan Zeuzem; Vincent Soriano; Tarik Asselah; Jean-Pierre Bronowicki; Ansgar W Lohse; Beat Müllhaupt; Marcus Schuchmann; Marc Bourlière; Maria Buti; Stuart K Roberts; Ed J Gane; Jerry O Stern; Richard Vinisko; George Kukolj; John-Paul Gallivan; Wulf-Otto Böcher; Federico J Mensa
Journal:  N Engl J Med       Date:  2013-08-15       Impact factor: 91.245

6.  Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay.

Authors:  Françoise Bouchardeau; Jean François Cantaloube; Stéphane Chevaliez; Christine Portal; Annie Razer; Jean-Jacques Lefrère; Jean Michel Pawlotsky; Philippe De Micco; Syria Laperche
Journal:  J Clin Microbiol       Date:  2007-01-24       Impact factor: 5.948

7.  Antiviral therapy of hepatitis C in 2014: do we need resistance testing?

Authors:  Maximilian David Schneider; Christoph Sarrazin
Journal:  Antiviral Res       Date:  2014-02-25       Impact factor: 5.970

8.  Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

Authors:  Mark S Sulkowski; David F Gardiner; Maribel Rodriguez-Torres; K Rajender Reddy; Tarek Hassanein; Ira Jacobson; Eric Lawitz; Anna S Lok; Federico Hinestrosa; Paul J Thuluvath; Howard Schwartz; David R Nelson; Gregory T Everson; Timothy Eley; Megan Wind-Rotolo; Shu-Pang Huang; Min Gao; Dennis Hernandez; Fiona McPhee; Diane Sherman; Robert Hindes; William Symonds; Claudio Pasquinelli; Dennis M Grasela
Journal:  N Engl J Med       Date:  2014-01-16       Impact factor: 91.245

9.  Hepatitis C virus subtyping based on sequencing of the C/E1 and NS5B genomic regions in comparison to a commercially available line probe assay.

Authors:  Ana Patrícia Avó; Ivone Agua-Doce; Ana Andrade; Elizabeth Pádua
Journal:  J Med Virol       Date:  2013-05       Impact factor: 2.327

10.  Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions.

Authors:  P Simmonds; D B Smith; F McOmish; P L Yap; J Kolberg; M S Urdea; E C Holmes
Journal:  J Gen Virol       Date:  1994-05       Impact factor: 3.891
View more
  11 in total

1.  A novel standardized deep sequencing-based assay for hepatitis C virus genotype determination.

Authors:  Christophe Rodriguez; Alexandre Soulier; Vanessa Demontant; Lila Poiteau; Mélanie Mercier-Darty; Magali Bouvier-Alias; Jean-Michel Pawlotsky; Stéphane Chevaliez
Journal:  Sci Rep       Date:  2018-03-08       Impact factor: 4.379

2.  NS3 genomic sequencing and phylogenetic analysis as alternative to a commercially available assay to reliably determine hepatitis C virus subtypes 1a and 1b.

Authors:  Karin Neukam; Alfredo P Martínez; Andrés C A Culasso; Ezequiel Ridruejo; Gabriel García; Federico A Di Lello
Journal:  PLoS One       Date:  2017-07-28       Impact factor: 3.240

3.  Development of a Method for Screening and Genotyping of HCV 1a, 1b, 2, 3, 4, and 6 Genotypes.

Authors:  Shrikant Dashrath Warkad; Satish Balasaheb Nimse; Keum-Soo Song; Taisun Kim
Journal:  ACS Omega       Date:  2020-05-08

4.  Reliable resolution of ambiguous hepatitis C virus genotype 1 results with the Abbott HCV Genotype Plus RUO assay.

Authors:  V Saludes; A Antuori; B Reinhardt; I Viciana; E Clavijo; L Schreiber; M Tenenbaum; F Rodriguez-Frias; J Quer; L Matas; E Martró
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

5.  Comparison of Sanger sequencing for hepatitis C virus genotyping with a commercial line probe assay in a tertiary hospital.

Authors:  Sylvie Goletti; Siméon Zuyten; Léonie Goeminne; Chris Verhofstede; Hector Rodriguez-Villalobos; Monique Bodeus; Peter Stärkel; Yves Horsmans; Benoît Kabamba-Mukadi
Journal:  BMC Infect Dis       Date:  2019-08-22       Impact factor: 3.090

6.  Using NS5B Sequencing for Hepatitis C Virus Genotyping Reveals Discordances with Commercial Platforms.

Authors:  Natalia Chueca; Isidro Rivadulla; Rubén Lovatti; Gabriel Reina; Ana Blanco; Jose Angel Fernandez-Caballero; Laura Cardeñoso; Javier Rodriguez-Granjer; Miriam Fernandez-Alonso; Antonio Aguilera; Marta Alvarez; Juan Carlos Galán; Federico García
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

7.  Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.

Authors:  Gretja Schnell; Rakesh Tripathi; Jill Beyer; Thomas Reisch; Preethi Krishnan; Liangjun Lu; Tatyana Dekhtyar; Coleen Hall; Regis A Vilchez; Tami Pilot-Matias; Christine Collins
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

8.  Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district.

Authors:  Ennio Polilli; Valeria Cento; Umberto Restelli; Francesca Ceccherini-Silberstein; Marianna Aragri; Velia Chiara Di Maio; Antonina Sciacca; Fiorenzo Santoleri; Paolo Fazii; Alberto Costantini; Carlo Federico Perno; Giustino Parruti
Journal:  Clinicoecon Outcomes Res       Date:  2016-09-14

9.  Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naïve Patients.

Authors:  Nadia Marascio; Grazia Pavia; Alessio Strazzulla; Tim Dierckx; Lize Cuypers; Bram Vrancken; Giorgio Settimo Barreca; Teresa Mirante; Donatella Malanga; Duarte Mendes Oliveira; Anne-Mieke Vandamme; Carlo Torti; Maria Carla Liberto; Alfredo Focà
Journal:  Int J Mol Sci       Date:  2016-08-27       Impact factor: 5.923

10.  Characterization of Samples Identified as Hepatitis C Virus Genotype 1 without Subtype by Abbott RealTime HCV Genotype II Assay Using the New Abbott HCV Genotype Plus RUO Test.

Authors:  Camelia Mokhtari; Anne Ebel; Birgit Reinhardt; Sandra Merlin; Stéphanie Proust; Anne-Marie Roque-Afonso
Journal:  J Clin Microbiol       Date:  2015-11-18       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.